| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SPINK4 |
| Uniprot No | O60575 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-86aa |
| 氨基酸序列 | GKLPFSRMPICEHMVESPTCSQMSNLVCGTDGLTYTNECQLCLARIKTKQ DIQIMKDGKCVDHHHHHH |
| 预测分子量 | 8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SPINK4重组蛋白的3篇参考文献及其简要摘要：
1. **文献名称**: *"Recombinant SPINK4 inhibits trypsin activity and reduces inflammation in a murine model of colitis"*
**作者**: Tanaka, Y., et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了重组SPINK4蛋白，验证其能有效抑制胰蛋白酶活性。动物实验表明，该蛋白可减轻小鼠结肠炎模型的肠道炎症，提示其在治疗炎症性肠病中的潜在应用。
2. **文献名称**: *"Characterization of SPINK4 as a selective protease inhibitor in the intestinal mucosa"*
**作者**: Smith, J.R., & Zhang, L.
**摘要**: 通过体外实验分析重组SPINK4的生化特性，发现其对肠道胰蛋白酶样蛋白酶具有特异性抑制作用。研究揭示了SPINK4在维持肠道黏膜屏障完整性中的关键调节作用。
3. **文献名称**: *"Production of bioactive human SPINK4 in Pichia pastoris and its functional analysis in pancreatic cancer cells"*
**作者**: Chen, X., et al.
**摘要**: 利用毕赤酵母系统高效表达具有生物活性的重组人SPINK4蛋白。细胞实验表明，该蛋白可抑制胰腺癌细胞侵袭迁移，其机制可能与调控基质金属蛋白酶(MMPs)活性相关。
注：以上文献信息为示例性概括，实际文献需通过PubMed/Google Scholar等平台检索确认。建议结合关键词"SPINK4 recombinant"+"expression"/"function"获取最新研究。
**Background of SPINK4 Recombinant Protein**
SPINK4 (Serine Peptidase Inhibitor Kazal Type 4) is a member of the SPINK family, known for regulating protease activity to maintain tissue homeostasis. Primarily expressed in gastrointestinal epithelial cells, especially in the colon and rectum, SPINK4 is implicated in mucosal defense and barrier integrity. It inhibits trypsin-like serine proteases, preventing excessive proteolytic damage during inflammation or infection. Dysregulation of SPINK4 has been linked to inflammatory bowel diseases (IBD), colorectal cancer, and other gastrointestinal disorders, highlighting its role in balancing protease-antiprotease activity.
The recombinant SPINK4 protein is engineered using genetic cloning techniques, often expressed in systems like *E. coli* or mammalian cells to ensure proper folding and post-translational modifications. This bioengineered form retains the functional domains of native SPINK4. including its inhibitory motifs, enabling studies on its biochemical interactions and therapeutic potential. Recombinant SPINK4 is utilized to investigate mechanisms of mucosal protection, protease inhibition, and disease pathways in experimental models.
Research applications include exploring its therapeutic value in IBD, where reduced SPINK4 levels correlate with disease severity, and in cancer, where it may suppress tumor-associated protease activity. Additionally, it serves as a tool for developing diagnostic biomarkers or therapies targeting protease dysregulation. Challenges remain in optimizing its stability, delivery, and specificity for clinical use. Overall, SPINK4 recombinant protein represents a critical reagent for advancing understanding of gastrointestinal biology and protease-mediated diseases.
×
